SARS-CoV-2 Donor-Recipient Immunity Transfer
- Status
- COMPLETED
- Phase
- N/A
Clinical Trials Related to Myelodysplastic Syndrome
Related studies linked through entity extraction aliases.
Venetoclax in Combination With ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
National Longitudinal Cohort of Hematological Diseases
- Status
- RECRUITING
- Phase
- N/A
Assessment of Chimerism and Relapse Post Bone Marrow/Hematopoietic Cell Transplant (HCT) Using AlloHeme Test
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- N/A
Clinical Relevance of DNMT and HDAC Gene SNP on the Response to Decitabine Therapy for Myelodysplastic Syndrome
- Status
- COMPLETED
- Phase
- N/A
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE2
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Evaluation of Antibody Response to High-Dose Seasonal Influenza Vaccination in Patients With Myeloid Malignancy Receiving Chemotherapy and Healthy Volunteers
- Status
- COMPLETED
- Phase
- EARLY_PHASE1
Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization
- Status
- COMPLETED
- Phase
- PHASE1
Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation
- Status
- COMPLETED
- Phase
- PHASE2
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
- Status
- RECRUITING
- Phase
- PHASE2
TBI Using IMRT (VMAT or Tomotherapy) for the Prevention of Pul Toxicities in Patients Undergoing Donor SCT
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
- Status
- SUSPENDED
- Phase
- PHASE1/PHASE2
Total Marrow and Lymphoid Irradiation as Conditioning Regimen Before Hematopoietic Cell Transplantation in Patients With Myelodysplastic Syndrome or Acute Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Status
- RECRUITING
- Phase
- PHASE1
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
- Status
- RECRUITING
- Phase
- PHASE2
A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies
- Status
- RECRUITING
- Phase
- PHASE1
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Status
- RECRUITING
- Phase
- PHASE2